Omeros Corporation (NASDAQ:OMER) shot up more than 60% in pre-market trading on Tuesday after the pharmaceutical company announced additional positive data for OMS721 …
Omeros Corporation (NASDAQ:OMER) announced additional positive data in the company’s Phase 2 clinical trial of OMS721 for the treatment of thrombotic microangiopathies (TMAs). …
Omeros Corporation (NASDAQ:OMER), in response to investor questions, announced that it plans to file a patent infringement lawsuit against Par Pharmaceutical, Inc. and its …
Omeros Corporation (NASDAQ:OMER), a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for large-market as well as orphan indications …
Wedbush analyst Liana Moussatos published a new list of upcoming catalysts for a variety emerging pharmaceuticals, including XOMA Corp (NASDAQ:XOMA), Intercept Pharmaceuticals Inc …
Seadrill Ltd (NYSE:SDRL) fell -2.13% in pre-market trading down to $8.
Omeros Corporation (NASDAQ:OMER) announced that the European Commission (EC) has granted marketing authorization for Omidria (phenylephrine and ketorolac injection) 1% / 0.3% in …
In a research report issued Thursday, Wedbush analyst Liana Moussatos reiterated an Outperform rating on Omeros Corporation (NASDAQ:OMER) with a price target of $61, …
Omeros Corporation (NASDAQ:OMER) announced that the U.S.
Wedbush’s healthcare analyst Liana Moussatos weighed in today with a favorable report on Omeros Corporation (NASDAQ:OMER), reiterating an Outperform rating and a $61 price target, which represents a …
